Clinical Trial: NCT06458413
Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Min Yan, MD |
| Information Provided By: | Henan Cancer Hospital |
| Last Update Posted: | 2026-10-16 |
Study Overview
Brief Summary
This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients.
This study was a single-arm, phase II study of patients with recurrent or metastatic HER2-negative breast cancer who had previously received chemotherapy regimens containing taxanes and/or anthracyclines were treated with a combination of utidelone capsules and capecitabine. The main objective was to explore the efficacy and safety of the combined regimen.
Official Title
Conditions
Intervention / Treatment
- Drug: Utidelone Capsule Plus Capecitabine
Other Study ID Numbers
- HNCH-MBC16
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Min Yan, MD |
| Information Provided By: | Henan Cancer Hospital |
| Last Update Posted: | 2026-10-16 |
Study Overview
Brief Summary
This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients.
This study was a single-arm, phase II study of patients with recurrent or metastatic HER2-negative breast cancer who had previously received chemotherapy regimens containing taxanes and/or anthracyclines were treated with a combination of utidelone capsules and capecitabine. The main objective was to explore the efficacy and safety of the combined regimen.
Official Title
Conditions
Intervention / Treatment
- Drug: Utidelone Capsule Plus Capecitabine
Other Study ID Numbers
- HNCH-MBC16